Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • Biotech Growth hikes gearing from zero to 10% to benefit from more M&A after hedge funds dump small drug firms
    • Unite raises £250m via seven-year unsecured bond
    • Morgan Stanley enters European active ETF market with four new funds
    • Midcap SIPs outperform largecap and smallcap funds with over 17% average returns in 10 years: WhiteOak Capital
    • Assets in retirement investment solutions rise by 28%
    • First Circle Capital completes $26mln final close for Africa Fund I
    • Quote on Gold ETFs or Gold Mutual Funds by Mr. Sandip Raichura, CEO of Retail Broking and Distribution & Director, PL Capital
    • Supermarket Income REIT (LSE:SUPR) Funding Strengthens Growth Outlook
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»Funds»Biotech Growth hikes gearing from zero to 10% to benefit from more M&A after hedge funds dump small drug firms
    Funds

    Biotech Growth hikes gearing from zero to 10% to benefit from more M&A after hedge funds dump small drug firms

    November 18, 2026


    Biotech Growth (BIOG) fund managers Geoff Hsu and Josh Golomb have raised gearing, or borrowing, to 10.3% after a two-month sell-off they believe will lead to even more bids in a sector where mergers and acquisitions had already surged from 2024 lows.

    Updates from the £243m investment trust show Hsu and Golomb have actively managed gearing this year, which they normally keep in a 5%-10% range, as they have responded to changing risks and opportunities in a turbulent market.

    Half-year results yesterday showed the pair cut BIOG’s gearing to zero in September from 3% at 31 March as fears of rising US interest rates hit the smaller companies weighted portfolio.

    Net asset value (NAV) fell 11.3% in September, reducing the six-month underlying portfolio return to 14.8%, underperforming the 21.6% gain in the Nasdaq Biotechnology index. This was discouraging for shareholders who had seen BIOG rebound 73.4% in the year to March after a four-year bear market. However, a narrowing in the share price discount helped by £15.7m of buybacks meant shareholders actually beat the benchmark with a 22.9% total return.

    BIOG’s factsheet for October showed a further 7.4% decline in NAV last month as larger biotech stocks benefited from investors switching out of expensive technology and artificial intelligence stocks to defensive sectors such as healthcare.

    By contrast, small-cap biotechs continued to face selling pressure, much of it from over-leveraged hedge funds slashing their exposure to smaller drug developers.

    “This degrossing meant that many of the companies we consider high quality that hedge funds held ‘long’ suffered the largest share price declines, while many of the lower quality companies that had been popular shorts outperformed as funds covered their short positions,” the managers said.

    Having already cut their small-cap holdings by 12 percentage points in the half-year period, the duo continued to reposition and tilt the portfolio further towards large caps.

    However, they believe that as yields on US government bonds, or Treasuries, stabilise, small and mid-cap biotech companies “will eventually recover from these transiently depressed levels”.

    The half-year saw BIOG benefit from five bids totalling $8bn for KalVista Pharmaceuticals, Esperion Therapeutics, Nuvalent, AtaiBeckley and Forte Biosciences at premiums of 26% to 58%.

    The managers are confident of more to come: “We believe the recent correction in biotech valuations could lead to an acceleration in M&A activity as large pharmaceutical companies seek to augment revenue growth ahead of patent cliffs in the early part of the next decade.

    “Opportunistic mid-cap companies also continue to assess potential transactions, further supporting the outlook for M&A across the sector. Against this backdrop, we believe that approximately 75% of our holdings as of 30 September are strong potential candidates for M&A.”

    According to figures from Life Science Daily, there have been 44 bids worth $162bn for  biotech companies over $1bn this year. By contrast, Factset data quoted in BIOG’s annual report showed $105bn of M&A last year up from just $32bn in 2024.

    BIOG shares stand on an 8.6% discount to NAV. At 31 October they had outperformed the Nasdaq Biotechnology’s three-year advance of 81.6% with an 89.5% NAV increase underpinning a 92.2% total return for shareholders. The five-year figures still show the impact of the 2022 crash with 15.3% and 14.6% NAV and share price gains compared to the benchmark’s 51.3% return.

    Our view

    Richard Williams, senior analyst at QuotedData, said: “The recovery in biotechnology stocks provided a significant boost to BIOG, although its NAV return fell short of the NASDAQ Biotechnology Index’s gain over the period. The underperformance was largely attributable to BIOG’s overweight exposure to smaller biotechnology companies, which were particularly vulnerable to the sharp rise in US Treasury yields in September. Nevertheless, stock selection delivered some notable successes, including Forte Biosciences, which was acquired for $2.2bn, while five portfolio companies attracted takeover offers during the period. This highlights the growing importance of M&A as larger pharmaceutical companies seek to replenish their drug pipelines, potentially providing further opportunities for BIOG’s small-cap holdings. With biotechnology valuations still considered attractive and takeover activity potentially accelerating, the outlook is encouraging, although BIOG’s emphasis on smaller companies means returns are likely to remain volatile.”





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    First Circle Capital completes $26mln final close for Africa Fund I

    November 18, 2026

    How the Houthis fund war effort and tighten grip on Yemen | Houthis News

    November 18, 2026

    Ringwood-based Forest Forge Theatre Company donates funds and resources as it prepares to close

    November 18, 2026
    Leave A Reply Cancel Reply

    Top Posts

    Biotech Growth hikes gearing from zero to 10% to benefit from more M&A after hedge funds dump small drug firms

    November 18, 2026

    Unite raises £250m via seven-year unsecured bond

    November 18, 2026

    ETFs Are Buying Cadeler (CDLR) on Thursday

    November 16, 2026

    Midcap SIPs outperform largecap and smallcap funds with over 17% average returns in 10 years: WhiteOak Capital

    November 18, 2026
    Don't Miss
    Funds

    Biotech Growth hikes gearing from zero to 10% to benefit from more M&A after hedge funds dump small drug firms

    November 18, 2026

    Biotech Growth (BIOG) fund managers Geoff Hsu and Josh Golomb have raised gearing, or borrowing,…

    Unite raises £250m via seven-year unsecured bond

    November 18, 2026

    Morgan Stanley enters European active ETF market with four new funds

    November 18, 2026

    Midcap SIPs outperform largecap and smallcap funds with over 17% average returns in 10 years: WhiteOak Capital

    November 18, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    Monzo launches ETF investing | MoneyWeek

    June 17, 2025

    Japan’s bonds rebound after rout, Nikkei falls for 5th session

    January 20, 2026

    An Easy Explanation of How Government Bonds Work

    November 7, 2026
    Our Picks

    Biotech Growth hikes gearing from zero to 10% to benefit from more M&A after hedge funds dump small drug firms

    November 18, 2026

    Unite raises £250m via seven-year unsecured bond

    November 18, 2026

    Morgan Stanley enters European active ETF market with four new funds

    November 18, 2026
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    🇮🇸 CPP Investments and Equinix complete atNorth acquisition to support growth of leading Nordic data center platform

    September 1, 2026
    © 2026 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.